<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165279</url>
  </required_header>
  <id_info>
    <org_study_id>ZEPHYR</org_study_id>
    <nct_id>NCT03165279</nct_id>
  </id_info>
  <brief_title>ZEnith AlPHa for AneurYsm Repair</brief_title>
  <acronym>ZEPHYR</acronym>
  <official_title>ZEnith AlPHa for AneurYsm Repair (ZEPHYR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippe Cuypers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively collect 'real world' performance data on the Zenith AlphaTM Abdominal
      Endovascular Graft for endovascular aneurysm repair, inside and outside instructions for use.
      To assess clinical efficacy of the low-profile device to treat patients with abdominal aortic
      aneurysm (AAA), to assess the use of the new delivery and deployment system of the Zenith
      AlphaTM Abdominal Endovascular Graft. Primary endpoint is the proportion of subjects who
      experience successful treatment at 1 year post-implant; defined by technical success and
      clinical success.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ZEPHYR registry has two major objectives:

        1. to prospectively collect 'real world' safety, durability and clinical performance data
           on the Zenith AlphaTM Abdominal Endovascular Graft in subjects with infrarenal abdominal
           aortic or aorto-iliac aneurysms.

        2. To increase the clinical evidence about the safety and effectiveness of the Zenith
           AlphaTM Abdominal Endovascular Graft by creating a database that can be pooled and/or
           compared with databases available on this and other stent graft systems.

      The ZEPHYR registry is a multi-center, post-market, non-randomized, single-arm prospective
      study. The study has no controls, as it is descriptive in nature. It will recruit
      approximately 450 subjects from high-volume sites across Germany and the BeNeLux. Study is
      open to consecutively enrolled subjects (20-50 per site) whou in the opinion of the
      investigator are candidates for endovascular AAA repair. The sites are recommended to
      schedule the subject's post-operative follow-up visits based on the current standard care in
      endovascular aneurysm repair (EVAR) therapy, which is generally at 1 month, 1 year and
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Successful treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of subjects who experience successful treatment at 1 year post-implant; defined by technical success and clinical success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of subjects who experience successful treatment at 1 month post-implant; defined by technical success and clinical success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of subjects who experience successful treatment at 2 years post-implant; defined by technical success and clinical success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>at 1 month, 1 year and at 2 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>at 1 month, 1 year and at 2 years</time_frame>
    <description>all-cause mortality, bowel ischemia, myocardial infarction, paraplegia, procedural blood loss &gt;1000 cc, renal failure requiring dialysis, respiratory failure, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm related mortality</measure>
    <time_frame>up to 30 days after index procedure or within 30 days after aneurysm-related reintervention</time_frame>
    <description>death from rupture, device-related death, death within 30 days of index procedure, death within 30 days of any aneurysm-related reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft migration of &gt;5mm (with 30 days measurement as baseline)</measure>
    <time_frame>at 1 year and at 2 years</time_frame>
    <description>Stent graft migration of &gt;5mm (with 30 days measurement as baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak</measure>
    <time_frame>at initial procedure, 1 month, 1 year and at 2 years</time_frame>
    <description>Any type of endoleak; tabulated by type (Ia, Ib, II or III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of secondary procedures to correct endoleaks</measure>
    <time_frame>From the day after the initial procedure up to 2 years after the initail procedure (which is the end of the follow up period for this registry)</time_frame>
    <description>Secondary procedures to correct endoleaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of secondary procedures for occlusion and/or kinking to restore stent graft function (endovascular and open procedures)</measure>
    <time_frame>From the day after the initial procedure up to 2 years after the initail procedure which is the end of the follow up period</time_frame>
    <description>Amount of secondary procedures for occlusion/kinking to restore stent graft function (endovascular and open surgical procedures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of secondary surgical interventions for stent graft infection</measure>
    <time_frame>From the day after the initial procedure up to 2 years after the initail procedure which is the end of the follow up period</time_frame>
    <description>Amount of secondary surgical intervention for stent graft infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of major lower limb amputation</measure>
    <time_frame>From the day after the initial procedure up to 2 years after the initail procedure (which is the end of the follow up period for this registry)</time_frame>
    <description>Amount of major lower limb amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Which kind of vascular access is used during surgical intervention</measure>
    <time_frame>at the primary procedure</time_frame>
    <description>Vascular access can either be unilateral, bilateral, open access or percutaneus access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access site complications</measure>
    <time_frame>during procedure up to 45 days</time_frame>
    <description>Hematoma, false aneurysm, vessel injury, primary conversion to femoral cutdown, surgical reintervention postoperative, false aneurysm at puncture site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of secondary open surgical interventions</measure>
    <time_frame>From the day after the initial procedure up to 2 years after the initail procedure (which is the end of the follow up period of this registry)</time_frame>
    <description>Amount of secondary open surgical interventions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Aneurysm</condition>
  <arm_group>
    <arm_group_label>Patient with AAA</arm_group_label>
    <description>Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Zenith Alpha Abdominal stentgraft</intervention_name>
    <arm_group_label>Patient with AAA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with defined AAA who are elegible for surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years or minimum age as required by local regulations

          -  Non-ruptured AAA with maximum diameter ≥50mm or enlargement &gt;5mm over 6 months and
             neck length ≥10mm (site-reported)

          -  Elective EVAR

          -  Intention to electively implant the Zenith AlphaTM AAA Endovascular Graft

          -  Signed informed consent form

        Exclusion Criteria:

          -  Intolerance to contrast media

          -  High probability of non-adherence to physician's follow-up requirements

          -  Current participation in a concurrent trial which may confound study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Cuypers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Zwetsloot, MSc</last_name>
    <phone>+31 (0)40 239 6349</phone>
    <email>jenny.zwetsloot@catharinaziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Janssens</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Oost Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Zwinnen</last_name>
    </contact>
    <investigator>
      <last_name>Herman Schroe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Vermassen, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Frank Vermassen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Frankfurt Höchst</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Rouhani</last_name>
    </contact>
    <investigator>
      <last_name>Guido Rouhani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Haack</last_name>
    </contact>
    <investigator>
      <last_name>Tilo Kölbel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelin Hund</last_name>
    </contact>
    <investigator>
      <last_name>Dittmar Bockler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Korn</last_name>
    </contact>
    <investigator>
      <last_name>Jan Brunkwall, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nürnberg Süd</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Wieser</last_name>
    </contact>
    <investigator>
      <last_name>Eric Verhoeven, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord Brabant</state>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Zwetsloot, MSc</last_name>
      <phone>+31(0)40 239 6349</phone>
      <email>jenny.zwetsloot@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Philippe Cuypers, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kakkhee Yeung, Dr</last_name>
    </contact>
    <investigator>
      <last_name>M. Truijers, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaHospital</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Wever, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jan Wever, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.J.F. Hollander</last_name>
    </contact>
    <investigator>
      <last_name>E.J.F. Hollander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G.W. Schurink</last_name>
    </contact>
    <investigator>
      <last_name>G.W. Schurink, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>B.M.E. Mees</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liesbeth Terlouw-Punt, M-ANP</last_name>
    </contact>
    <contact_backup>
      <last_name>Patricia van Mierlo-van den Broek</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bram Fioole, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Philippe Cuypers</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

